Sulfonylureas may be associated with beneficial outcomes in patients with type II diabetes mellitus who experience an acute ischaemic stroke

Author：

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1610, 2007-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk Factors for Developing Pneumonia in Patients with Diabetes Mellitus Following Acute Ischaemic Stroke

By Zhang X Wang F Zhang Y Ge Z

The Journal of International Medical Research, Vol. 40, Iss. 5, 2012-09 ,pp. : 1860-1865

Field House Publishing

Access to resources Recommend Favorite

Ancrod may not provide clinical benefit to patients with acute ischaemic stroke

Inpharma, Vol. 1, Iss. 1566, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Angiotensin II blockade may prevent type 2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1511, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Metformin may reduce the risk of cancer in patients with type 2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1491, 2005-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus

By Swen Jesse J Wessels Judith AM Krabben Annemarie Assendelft Willem JJ Guchelaar Henk-Jan

Pharmacogenomics, Vol. 11, Iss. 11, 2010-11 ,pp. : 1517-1523

Future Medicine

Access to resources Recommend Favorite